

Global Extended Oral Antibiotics Market Growth 2026-2032

<https://marketpublishers.com/r/G9332D1F97CEEN.html>

Date: July 2026

Pages: 177

Price: US\$ 3,660.00 (Single User License)

ID: G9332D1F97CEEN

Abstracts

The global Extended Oral Antibiotics market size is predicted to grow from US\$ 2889 million in 2025 to US\$ 4246 million in 2032; it is expected to grow at a CAGR of 5.7% from 2026 to 2032.

Extended Oral Antibiotics refer to antibiotic drug products administered via the oral route that are formulated to achieve prolonged therapeutic plasma concentrations through modified-release drug delivery technologies or standard oral antibiotic formulations prescribed for extended treatment durations for complicated or chronic bacterial infections. In 2025, global wide neck baby bottles production reached approximately 777,134 K unit, with an average global market price of around USD 3,800 per K unit. A factory gross profit of USD 760 per K unit with 20% gross margin. A single line full machine capacity production is around 150 K unit per line per year. The upstream is dependent on active pharmaceutical ingredients, formulations components and intermediates. The downstream demand is concentrated in hospitals, specialty clinics and pharmacy. Extended oral antibiotic use for dental infections is generally reserved for severe or spreading condition such as tooth abscess. it's control bacterial spread. China market is driven by large antibiotic production capacity and expanding healthcare coverage.

United States market for Extended Oral Antibiotics is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Extended Oral Antibiotics is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Extended Oral Antibiotics is estimated to increase from US\$ million in

2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Extended Oral Antibiotics players cover Pfizer Inc., GSK plc., Merck & Co., Inc., Novartis AG, Sanofi S.A., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the "Extended Oral Antibiotics Industry Forecast" looks at past sales and reviews total world Extended Oral Antibiotics sales in 2025, providing a comprehensive analysis by region and market sector of projected Extended Oral Antibiotics sales for 2026 through 2032. With Extended Oral Antibiotics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Extended Oral Antibiotics industry.

This Insight Report provides a comprehensive analysis of the global Extended Oral Antibiotics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Extended Oral Antibiotics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Extended Oral Antibiotics market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Extended Oral Antibiotics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Extended Oral Antibiotics.

This report presents a comprehensive overview, market shares, and growth opportunities of Extended Oral Antibiotics market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

Extended Release Oral Antibiotics

Oral Penicillin Derivatives

Oral Cephalosporins

Oral Macrolides

Others

Segmentation by Antibiotic Spectrum:

Narrow Spectrum Antibiotics

Broad Spectrum Antibiotics

Segmentation by Treatment Duration:

Short Extended Course (7-10 Days)

Standard Extended Course (10-14 Days)

Prolonged Course (14-28 Days)

Long Term Suppression (>28 Days to Months)

Others

Segmentation by Application:

Hospitals

Clinics

Pharmacy

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

Pfizer Inc.

GSK plc.

Merck & Co., Inc.

Novartis AG

Sanofi S.A.

Teva Pharmaceutical Industries

Viartis Inc.

Aurobindo Pharma Ltd

Sun Pharmaceutical Industries Ltd

Dr. Reddy's Laboratories Ltd

Cipla Ltd

Lupin Ltd

Zhejiang Hisun Pharmaceutical Co., Ltd

Takeda Pharmaceutical Company Ltd

Daiichi Sankyo Company Ltd

Meiji Seika Pharma Co., Ltd

Boryung Co., Ltd

Orchid Pharma Ltd

CSPC Pharmaceutical Group Ltd

Aspen Pharmacare Holdings Ltd

North China Pharmaceutical Group Corp

Shandong Lukang Pharmaceutical Co., Ltd

Zentiva

RedHill Biopharma Ltd

TaiGen Biotechnology Co., Ltd

Taiwan Biotech Co., Ltd

Centrient Pharmaceuticals

Nabriva Therapeutics plc

Melinta Therapeutics Inc.

Lonza Group

Key Questions Addressed in this Report

What is the 10-year outlook for the global Extended Oral Antibiotics market?

What factors are driving Extended Oral Antibiotics market growth, globally and by

region?

Which technologies are poised for the fastest growth by market and region?

How do Extended Oral Antibiotics market opportunities vary by end market size?

How does Extended Oral Antibiotics break out by Type, by Application?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Extended Oral Antibiotics Annual Sales 2021-2032
 - 2.1.2 World Current & Future Analysis for Extended Oral Antibiotics by Geographic Region, 2021, 2025 & 2032
 - 2.1.3 World Current & Future Analysis for Extended Oral Antibiotics by Country/Region, 2021, 2025 & 2032
- 2.2 Extended Oral Antibiotics Segment by Type
 - 2.2.1 Extended Release Oral Antibiotics
 - 2.2.2 Oral Penicillin Derivatives
 - 2.2.3 Oral Cephalosporins
 - 2.2.4 Oral Macrolides
 - 2.2.5 Others
 - 2.2.6 Extended Oral Antibiotics Sales by Type
 - 2.2.6.1 Global Extended Oral Antibiotics Sales Market Share by Type (2021-2026)
 - 2.2.6.2 Global Extended Oral Antibiotics Revenue and Market Share by Type (2021-2026)
 - 2.2.6.3 Global Extended Oral Antibiotics Sale Price by Type (2021-2026)
- 2.3 Extended Oral Antibiotics Segment by Antibiotic Spectrum
 - 2.3.1 Narrow Spectrum Antibiotics
 - 2.3.2 Broad Spectrum Antibiotics
 - 2.3.3 Extended Oral Antibiotics Sales by Antibiotic Spectrum
 - 2.3.3.1 Global Extended Oral Antibiotics Sales Market Share by Antibiotic Spectrum (2021-2026)
 - 2.3.3.2 Global Extended Oral Antibiotics Revenue and Market Share by Antibiotic

Spectrum (2021-2026)

2.3.3.3 Global Extended Oral Antibiotics Sale Price by Antibiotic Spectrum (2021-2026)

2.4 Extended Oral Antibiotics Segment by Treatment Duration

2.4.1 Short Extended Course (7-10 Days)

2.4.2 Standard Extended Course (10-14 Days)

2.4.3 Prolonged Course (14-28 Days)

2.4.4 Long Term Suppression (>28 Days to Months)

2.4.5 Others

2.4.6 Extended Oral Antibiotics Sales by Treatment Duration

2.4.6.1 Global Extended Oral Antibiotics Sales Market Share by Treatment Duration (2021-2026)

2.4.6.2 Global Extended Oral Antibiotics Revenue and Market Share by Treatment Duration (2021-2026)

2.4.6.3 Global Extended Oral Antibiotics Sale Price by Treatment Duration (2021-2026)

2.5 Extended Oral Antibiotics Segment by Application

2.5.1 Hospitals

2.5.2 Clinics

2.5.3 Pharmacy

2.5.4 Others

2.5.5 Extended Oral Antibiotics Sales by Application

2.5.5.1 Global Extended Oral Antibiotics Sale Market Share by Application (2021-2026)

2.5.5.2 Global Extended Oral Antibiotics Revenue and Market Share by Application (2021-2026)

2.5.5.3 Global Extended Oral Antibiotics Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Extended Oral Antibiotics Breakdown Data by Company

3.1.1 Global Extended Oral Antibiotics Annual Sales by Company (2021-2026)

3.1.2 Global Extended Oral Antibiotics Sales Market Share by Company (2021-2026)

3.2 Global Extended Oral Antibiotics Annual Revenue by Company (2021-2026)

3.2.1 Global Extended Oral Antibiotics Revenue by Company (2021-2026)

3.2.2 Global Extended Oral Antibiotics Revenue Market Share by Company (2021-2026)

3.3 Global Extended Oral Antibiotics Sale Price by Company

3.4 Key Manufacturers Extended Oral Antibiotics Producing Area Distribution, Sales

Area, Product Type

3.4.1 Key Manufacturers Extended Oral Antibiotics Product Location Distribution

3.4.2 Players Extended Oral Antibiotics Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR EXTENDED ORAL ANTIBIOTICS BY GEOGRAPHIC REGION

4.1 World Historic Extended Oral Antibiotics Market Size by Geographic Region (2021-2026)

4.1.1 Global Extended Oral Antibiotics Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Extended Oral Antibiotics Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic Extended Oral Antibiotics Market Size by Country/Region (2021-2026)

4.2.1 Global Extended Oral Antibiotics Annual Sales by Country/Region (2021-2026)

4.2.2 Global Extended Oral Antibiotics Annual Revenue by Country/Region (2021-2026)

4.3 Americas Extended Oral Antibiotics Sales Growth

4.4 APAC Extended Oral Antibiotics Sales Growth

4.5 Europe Extended Oral Antibiotics Sales Growth

4.6 Middle East & Africa Extended Oral Antibiotics Sales Growth

5 AMERICAS

5.1 Americas Extended Oral Antibiotics Sales by Country

5.1.1 Americas Extended Oral Antibiotics Sales by Country (2021-2026)

5.1.2 Americas Extended Oral Antibiotics Revenue by Country (2021-2026)

5.2 Americas Extended Oral Antibiotics Sales by Type (2021-2026)

5.3 Americas Extended Oral Antibiotics Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Extended Oral Antibiotics Sales by Region

6.1.1 APAC Extended Oral Antibiotics Sales by Region (2021-2026)

6.1.2 APAC Extended Oral Antibiotics Revenue by Region (2021-2026)

6.2 APAC Extended Oral Antibiotics Sales by Type (2021-2026)

6.3 APAC Extended Oral Antibiotics Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Extended Oral Antibiotics by Country

7.1.1 Europe Extended Oral Antibiotics Sales by Country (2021-2026)

7.1.2 Europe Extended Oral Antibiotics Revenue by Country (2021-2026)

7.2 Europe Extended Oral Antibiotics Sales by Type (2021-2026)

7.3 Europe Extended Oral Antibiotics Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Extended Oral Antibiotics by Country

8.1.1 Middle East & Africa Extended Oral Antibiotics Sales by Country (2021-2026)

8.1.2 Middle East & Africa Extended Oral Antibiotics Revenue by Country (2021-2026)

8.2 Middle East & Africa Extended Oral Antibiotics Sales by Type (2021-2026)

8.3 Middle East & Africa Extended Oral Antibiotics Sales by Application (2021-2026)

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Extended Oral Antibiotics

10.3 Manufacturing Process Analysis of Extended Oral Antibiotics

10.4 Industry Chain Structure of Extended Oral Antibiotics

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Extended Oral Antibiotics Distributors

11.3 Extended Oral Antibiotics Customer

12 WORLD FORECAST REVIEW FOR EXTENDED ORAL ANTIBIOTICS BY GEOGRAPHIC REGION

12.1 Global Extended Oral Antibiotics Market Size Forecast by Region

12.1.1 Global Extended Oral Antibiotics Forecast by Region (2027-2032)

12.1.2 Global Extended Oral Antibiotics Annual Revenue Forecast by Region (2027-2032)

12.2 Americas Forecast by Country (2027-2032)

12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Extended Oral Antibiotics Forecast by Type (2027-2032)

12.7 Global Extended Oral Antibiotics Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 Pfizer Inc.

13.1.1 Pfizer Inc. Company Information

13.1.2 Pfizer Inc. Extended Oral Antibiotics Product Portfolios and Specifications

13.1.3 Pfizer Inc. Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin
(2021-2026)

13.1.4 Pfizer Inc. Main Business Overview

13.1.5 Pfizer Inc. Latest Developments

13.2 GSK plc.

13.2.1 GSK plc. Company Information

13.2.2 GSK plc. Extended Oral Antibiotics Product Portfolios and Specifications

13.2.3 GSK plc. Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin
(2021-2026)

13.2.4 GSK plc. Main Business Overview

13.2.5 GSK plc. Latest Developments

13.3 Merck & Co., Inc.

13.3.1 Merck & Co., Inc. Company Information

13.3.2 Merck & Co., Inc. Extended Oral Antibiotics Product Portfolios and
Specifications

13.3.3 Merck & Co., Inc. Extended Oral Antibiotics Sales, Revenue, Price and Gross
Margin (2021-2026)

13.3.4 Merck & Co., Inc. Main Business Overview

13.3.5 Merck & Co., Inc. Latest Developments

13.4 Novartis AG

13.4.1 Novartis AG Company Information

13.4.2 Novartis AG Extended Oral Antibiotics Product Portfolios and Specifications

13.4.3 Novartis AG Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin
(2021-2026)

13.4.4 Novartis AG Main Business Overview

13.4.5 Novartis AG Latest Developments

13.5 Sanofi S.A.

13.5.1 Sanofi S.A. Company Information

13.5.2 Sanofi S.A. Extended Oral Antibiotics Product Portfolios and Specifications

13.5.3 Sanofi S.A. Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin
(2021-2026)

13.5.4 Sanofi S.A. Main Business Overview

13.5.5 Sanofi S.A. Latest Developments

13.6 Teva Pharmaceutical Industries

13.6.1 Teva Pharmaceutical Industries Company Information

13.6.2 Teva Pharmaceutical Industries Extended Oral Antibiotics Product Portfolios and Specifications

13.6.3 Teva Pharmaceutical Industries Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)

13.6.4 Teva Pharmaceutical Industries Main Business Overview

13.6.5 Teva Pharmaceutical Industries Latest Developments

13.7 Viatris Inc.

13.7.1 Viatris Inc. Company Information

13.7.2 Viatris Inc. Extended Oral Antibiotics Product Portfolios and Specifications

13.7.3 Viatris Inc. Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)

13.7.4 Viatris Inc. Main Business Overview

13.7.5 Viatris Inc. Latest Developments

13.8 Aurobindo Pharma Ltd

13.8.1 Aurobindo Pharma Ltd Company Information

13.8.2 Aurobindo Pharma Ltd Extended Oral Antibiotics Product Portfolios and Specifications

13.8.3 Aurobindo Pharma Ltd Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)

13.8.4 Aurobindo Pharma Ltd Main Business Overview

13.8.5 Aurobindo Pharma Ltd Latest Developments

13.9 Sun Pharmaceutical Industries Ltd

13.9.1 Sun Pharmaceutical Industries Ltd Company Information

13.9.2 Sun Pharmaceutical Industries Ltd Extended Oral Antibiotics Product Portfolios and Specifications

13.9.3 Sun Pharmaceutical Industries Ltd Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)

13.9.4 Sun Pharmaceutical Industries Ltd Main Business Overview

13.9.5 Sun Pharmaceutical Industries Ltd Latest Developments

13.10 Dr. Reddy's Laboratories Ltd

13.10.1 Dr. Reddy's Laboratories Ltd Company Information

13.10.2 Dr. Reddy's Laboratories Ltd Extended Oral Antibiotics Product Portfolios and Specifications

13.10.3 Dr. Reddy's Laboratories Ltd Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)

13.10.4 Dr. Reddy's Laboratories Ltd Main Business Overview

13.10.5 Dr. Reddy's Laboratories Ltd Latest Developments

13.11 Cipla Ltd

13.11.1 Cipla Ltd Company Information

- 13.11.2 Cipla Ltd Extended Oral Antibiotics Product Portfolios and Specifications
- 13.11.3 Cipla Ltd Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)
- 13.11.4 Cipla Ltd Main Business Overview
- 13.11.5 Cipla Ltd Latest Developments
- 13.12 Lupin Ltd
 - 13.12.1 Lupin Ltd Company Information
 - 13.12.2 Lupin Ltd Extended Oral Antibiotics Product Portfolios and Specifications
 - 13.12.3 Lupin Ltd Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.12.4 Lupin Ltd Main Business Overview
 - 13.12.5 Lupin Ltd Latest Developments
- 13.13 Zhejiang Hisun Pharmaceutical Co., Ltd
 - 13.13.1 Zhejiang Hisun Pharmaceutical Co., Ltd Company Information
 - 13.13.2 Zhejiang Hisun Pharmaceutical Co., Ltd Extended Oral Antibiotics Product Portfolios and Specifications
 - 13.13.3 Zhejiang Hisun Pharmaceutical Co., Ltd Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.13.4 Zhejiang Hisun Pharmaceutical Co., Ltd Main Business Overview
 - 13.13.5 Zhejiang Hisun Pharmaceutical Co., Ltd Latest Developments
- 13.14 Takeda Pharmaceutical Company Ltd
 - 13.14.1 Takeda Pharmaceutical Company Ltd Company Information
 - 13.14.2 Takeda Pharmaceutical Company Ltd Extended Oral Antibiotics Product Portfolios and Specifications
 - 13.14.3 Takeda Pharmaceutical Company Ltd Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.14.4 Takeda Pharmaceutical Company Ltd Main Business Overview
 - 13.14.5 Takeda Pharmaceutical Company Ltd Latest Developments
- 13.15 Daiichi Sankyo Company Ltd
 - 13.15.1 Daiichi Sankyo Company Ltd Company Information
 - 13.15.2 Daiichi Sankyo Company Ltd Extended Oral Antibiotics Product Portfolios and Specifications
 - 13.15.3 Daiichi Sankyo Company Ltd Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)
 - 13.15.4 Daiichi Sankyo Company Ltd Main Business Overview
 - 13.15.5 Daiichi Sankyo Company Ltd Latest Developments
- 13.16 Meiji Seika Pharma Co., Ltd
 - 13.16.1 Meiji Seika Pharma Co., Ltd Company Information
 - 13.16.2 Meiji Seika Pharma Co., Ltd Extended Oral Antibiotics Product Portfolios and

Specifications

13.16.3 Meiji Seika Pharma Co., Ltd Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)

13.16.4 Meiji Seika Pharma Co., Ltd Main Business Overview

13.16.5 Meiji Seika Pharma Co., Ltd Latest Developments

13.17 Boryung Co., Ltd

13.17.1 Boryung Co., Ltd Company Information

13.17.2 Boryung Co., Ltd Extended Oral Antibiotics Product Portfolios and Specifications

13.17.3 Boryung Co., Ltd Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)

13.17.4 Boryung Co., Ltd Main Business Overview

13.17.5 Boryung Co., Ltd Latest Developments

13.18 Orchid Pharma Ltd

13.18.1 Orchid Pharma Ltd Company Information

13.18.2 Orchid Pharma Ltd Extended Oral Antibiotics Product Portfolios and Specifications

13.18.3 Orchid Pharma Ltd Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)

13.18.4 Orchid Pharma Ltd Main Business Overview

13.18.5 Orchid Pharma Ltd Latest Developments

13.19 CSPC Pharmaceutical Group Ltd

13.19.1 CSPC Pharmaceutical Group Ltd Company Information

13.19.2 CSPC Pharmaceutical Group Ltd Extended Oral Antibiotics Product Portfolios and Specifications

13.19.3 CSPC Pharmaceutical Group Ltd Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)

13.19.4 CSPC Pharmaceutical Group Ltd Main Business Overview

13.19.5 CSPC Pharmaceutical Group Ltd Latest Developments

13.20 Aspen Pharmacare Holdings Ltd

13.20.1 Aspen Pharmacare Holdings Ltd Company Information

13.20.2 Aspen Pharmacare Holdings Ltd Extended Oral Antibiotics Product Portfolios and Specifications

13.20.3 Aspen Pharmacare Holdings Ltd Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)

13.20.4 Aspen Pharmacare Holdings Ltd Main Business Overview

13.20.5 Aspen Pharmacare Holdings Ltd Latest Developments

13.21 North China Pharmaceutical Group Corp

13.21.1 North China Pharmaceutical Group Corp Company Information

13.21.2 North China Pharmaceutical Group Corp Extended Oral Antibiotics Product Portfolios and Specifications

13.21.3 North China Pharmaceutical Group Corp Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)

13.21.4 North China Pharmaceutical Group Corp Main Business Overview

13.21.5 North China Pharmaceutical Group Corp Latest Developments

13.22 Shandong Lukang Pharmaceutical Co., Ltd

13.22.1 Shandong Lukang Pharmaceutical Co., Ltd Company Information

13.22.2 Shandong Lukang Pharmaceutical Co., Ltd Extended Oral Antibiotics Product Portfolios and Specifications

13.22.3 Shandong Lukang Pharmaceutical Co., Ltd Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)

13.22.4 Shandong Lukang Pharmaceutical Co., Ltd Main Business Overview

13.22.5 Shandong Lukang Pharmaceutical Co., Ltd Latest Developments

13.23 Zentiva

13.23.1 Zentiva Company Information

13.23.2 Zentiva Extended Oral Antibiotics Product Portfolios and Specifications

13.23.3 Zentiva Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)

13.23.4 Zentiva Main Business Overview

13.23.5 Zentiva Latest Developments

13.24 RedHill Biopharma Ltd

13.24.1 RedHill Biopharma Ltd Company Information

13.24.2 RedHill Biopharma Ltd Extended Oral Antibiotics Product Portfolios and Specifications

13.24.3 RedHill Biopharma Ltd Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)

13.24.4 RedHill Biopharma Ltd Main Business Overview

13.24.5 RedHill Biopharma Ltd Latest Developments

13.25 TaiGen Biotechnology Co., Ltd

13.25.1 TaiGen Biotechnology Co., Ltd Company Information

13.25.2 TaiGen Biotechnology Co., Ltd Extended Oral Antibiotics Product Portfolios and Specifications

13.25.3 TaiGen Biotechnology Co., Ltd Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)

13.25.4 TaiGen Biotechnology Co., Ltd Main Business Overview

13.25.5 TaiGen Biotechnology Co., Ltd Latest Developments

13.26 Taiwan Biotech Co., Ltd

13.26.1 Taiwan Biotech Co., Ltd Company Information

13.26.2 Taiwan Biotech Co., Ltd Extended Oral Antibiotics Product Portfolios and Specifications

13.26.3 Taiwan Biotech Co., Ltd Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)

13.26.4 Taiwan Biotech Co., Ltd Main Business Overview

13.26.5 Taiwan Biotech Co., Ltd Latest Developments

13.27 Centrient Pharmaceuticals

13.27.1 Centrient Pharmaceuticals Company Information

13.27.2 Centrient Pharmaceuticals Extended Oral Antibiotics Product Portfolios and Specifications

13.27.3 Centrient Pharmaceuticals Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)

13.27.4 Centrient Pharmaceuticals Main Business Overview

13.27.5 Centrient Pharmaceuticals Latest Developments

13.28 Nabriva Therapeutics plc

13.28.1 Nabriva Therapeutics plc Company Information

13.28.2 Nabriva Therapeutics plc Extended Oral Antibiotics Product Portfolios and Specifications

13.28.3 Nabriva Therapeutics plc Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)

13.28.4 Nabriva Therapeutics plc Main Business Overview

13.28.5 Nabriva Therapeutics plc Latest Developments

13.29 Melinta Therapeutics Inc.

13.29.1 Melinta Therapeutics Inc. Company Information

13.29.2 Melinta Therapeutics Inc. Extended Oral Antibiotics Product Portfolios and Specifications

13.29.3 Melinta Therapeutics Inc. Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)

13.29.4 Melinta Therapeutics Inc. Main Business Overview

13.29.5 Melinta Therapeutics Inc. Latest Developments

13.30 Lonza Group

13.30.1 Lonza Group Company Information

13.30.2 Lonza Group Extended Oral Antibiotics Product Portfolios and Specifications

13.30.3 Lonza Group Extended Oral Antibiotics Sales, Revenue, Price and Gross Margin (2021-2026)

13.30.4 Lonza Group Main Business Overview

13.30.5 Lonza Group Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

- Table 1. Extended Oral Antibiotics Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Table 2. Extended Oral Antibiotics Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)
- Table 3. Major Players of Extended Release Oral Antibiotics
- Table 4. Major Players of Oral Penicillin Derivatives
- Table 5. Major Players of Oral Cephalosporins
- Table 6. Major Players of Oral Macrolides
- Table 7. Major Players of Others
- Table 8. Global Extended Oral Antibiotics Sales by Type (2021-2026) & (K Units)
- Table 9. Global Extended Oral Antibiotics Sales Market Share by Type (2021-2026)
- Table 10. Global Extended Oral Antibiotics Revenue by Type (2021-2026) & (\$ million)
- Table 11. Global Extended Oral Antibiotics Revenue Market Share by Type (2021-2026)
- Table 12. Global Extended Oral Antibiotics Sale Price by Type (2021-2026) & (US\$/Unit)
- Table 13. Major Players of Narrow Spectrum Antibiotics
- Table 14. Major Players of Broad Spectrum Antibiotics
- Table 15. Global Extended Oral Antibiotics Sales by Antibiotic Spectrum (2021-2026) & (K Units)
- Table 16. Global Extended Oral Antibiotics Sales Market Share by Antibiotic Spectrum (2021-2026)
- Table 17. Global Extended Oral Antibiotics Revenue by Antibiotic Spectrum (2021-2026) & (\$ million)
- Table 18. Global Extended Oral Antibiotics Revenue Market Share by Antibiotic Spectrum (2021-2026)
- Table 19. Global Extended Oral Antibiotics Sale Price by Antibiotic Spectrum (2021-2026) & (US\$/Unit)
- Table 20. Major Players of Short Extended Course (7-10 Days)
- Table 21. Major Players of Standard Extended Course (10-14 Days)
- Table 22. Major Players of Prolonged Course (14-28 Days)
- Table 23. Major Players of Long Term Suppression (>28 Days to Months)
- Table 24. Major Players of Others
- Table 25. Global Extended Oral Antibiotics Sales by Treatment Duration (2021-2026) & (K Units)
- Table 26. Global Extended Oral Antibiotics Sales Market Share by Treatment Duration

(2021-2026)

Table 27. Global Extended Oral Antibiotics Revenue by Treatment Duration (2021-2026) & (\$ million)

Table 28. Global Extended Oral Antibiotics Revenue Market Share by Treatment Duration (2021-2026)

Table 29. Global Extended Oral Antibiotics Sale Price by Treatment Duration (2021-2026) & (US\$/Unit)

Table 30. Global Extended Oral Antibiotics Sale by Application (2021-2026) & (K Units)

Table 31. Global Extended Oral Antibiotics Sale Market Share by Application (2021-2026)

Table 32. Global Extended Oral Antibiotics Revenue by Application (2021-2026) & (\$ million)

Table 33. Global Extended Oral Antibiotics Revenue Market Share by Application (2021-2026)

Table 34. Global Extended Oral Antibiotics Sale Price by Application (2021-2026) & (US\$/Unit)

Table 35. Global Extended Oral Antibiotics Sales by Company (2021-2026) & (K Units)

Table 36. Global Extended Oral Antibiotics Sales Market Share by Company (2021-2026)

Table 37. Global Extended Oral Antibiotics Revenue by Company (2021-2026) & (\$ millions)

Table 38. Global Extended Oral Antibiotics Revenue Market Share by Company (2021-2026)

Table 39. Global Extended Oral Antibiotics Sale Price by Company (2021-2026) & (US\$/Unit)

Table 40. Key Manufacturers Extended Oral Antibiotics Producing Area Distribution and Sales Area

Table 41. Players Extended Oral Antibiotics Products Offered

Table 42. Extended Oral Antibiotics Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 43. New Products and Potential Entrants

Table 44. Market M&A Activity & Strategy

Table 45. Global Extended Oral Antibiotics Sales by Geographic Region (2021-2026) & (K Units)

Table 46. Global Extended Oral Antibiotics Sales Market Share Geographic Region (2021-2026)

Table 47. Global Extended Oral Antibiotics Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 48. Global Extended Oral Antibiotics Revenue Market Share by Geographic

Region (2021-2026)

Table 49. Global Extended Oral Antibiotics Sales by Country/Region (2021-2026) & (K Units)

Table 50. Global Extended Oral Antibiotics Sales Market Share by Country/Region (2021-2026)

Table 51. Global Extended Oral Antibiotics Revenue by Country/Region (2021-2026) & (\$ millions)

Table 52. Global Extended Oral Antibiotics Revenue Market Share by Country/Region (2021-2026)

Table 53. Americas Extended Oral Antibiotics Sales by Country (2021-2026) & (K Units)

Table 54. Americas Extended Oral Antibiotics Sales Market Share by Country (2021-2026)

Table 55. Americas Extended Oral Antibiotics Revenue by Country (2021-2026) & (\$ millions)

Table 56. Americas Extended Oral Antibiotics Sales by Type (2021-2026) & (K Units)

Table 57. Americas Extended Oral Antibiotics Sales by Application (2021-2026) & (K Units)

Table 58. APAC Extended Oral Antibiotics Sales by Region (2021-2026) & (K Units)

Table 59. APAC Extended Oral Antibiotics Sales Market Share by Region (2021-2026)

Table 60. APAC Extended Oral Antibiotics Revenue by Region (2021-2026) & (\$ millions)

Table 61. APAC Extended Oral Antibiotics Sales by Type (2021-2026) & (K Units)

Table 62. APAC Extended Oral Antibiotics Sales by Application (2021-2026) & (K Units)

Table 63. Europe Extended Oral Antibiotics Sales by Country (2021-2026) & (K Units)

Table 64. Europe Extended Oral Antibiotics Revenue by Country (2021-2026) & (\$ millions)

Table 65. Europe Extended Oral Antibiotics Sales by Type (2021-2026) & (K Units)

Table 66. Europe Extended Oral Antibiotics Sales by Application (2021-2026) & (K Units)

Table 67. Middle East & Africa Extended Oral Antibiotics Sales by Country (2021-2026) & (K Units)

Table 68. Middle East & Africa Extended Oral Antibiotics Revenue Market Share by Country (2021-2026)

Table 69. Middle East & Africa Extended Oral Antibiotics Sales by Type (2021-2026) & (K Units)

Table 70. Middle East & Africa Extended Oral Antibiotics Sales by Application (2021-2026) & (K Units)

Table 71. Key Market Drivers & Growth Opportunities of Extended Oral Antibiotics

Table 72. Key Market Challenges & Risks of Extended Oral Antibiotics

Table 73. Key Industry Trends of Extended Oral Antibiotics
Table 74. Extended Oral Antibiotics Raw Material
Table 75. Key Suppliers of Raw Materials
Table 76. Extended Oral Antibiotics Distributors List
Table 77. Extended Oral Antibiotics Customer List
Table 78. Global Extended Oral Antibiotics Sales Forecast by Region (2027-2032) & (K Units)
Table 79. Global Extended Oral Antibiotics Revenue Forecast by Region (2027-2032) & (\$ millions)
Table 80. Americas Extended Oral Antibiotics Sales Forecast by Country (2027-2032) & (K Units)
Table 81. Americas Extended Oral Antibiotics Annual Revenue Forecast by Country (2027-2032) & (\$ millions)
Table 82. APAC Extended Oral Antibiotics Sales Forecast by Region (2027-2032) & (K Units)
Table 83. APAC Extended Oral Antibiotics Annual Revenue Forecast by Region (2027-2032) & (\$ millions)
Table 84. Europe Extended Oral Antibiotics Sales Forecast by Country (2027-2032) & (K Units)
Table 85. Europe Extended Oral Antibiotics Revenue Forecast by Country (2027-2032) & (\$ millions)
Table 86. Middle East & Africa Extended Oral Antibiotics Sales Forecast by Country (2027-2032) & (K Units)
Table 87. Middle East & Africa Extended Oral Antibiotics Revenue Forecast by Country (2027-2032) & (\$ millions)
Table 88. Global Extended Oral Antibiotics Sales Forecast by Type (2027-2032) & (K Units)
Table 89. Global Extended Oral Antibiotics Revenue Forecast by Type (2027-2032) & (\$ millions)
Table 90. Global Extended Oral Antibiotics Sales Forecast by Application (2027-2032) & (K Units)
Table 91. Global Extended Oral Antibiotics Revenue Forecast by Application (2027-2032) & (\$ millions)
Table 92. Pfizer Inc. Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors
Table 93. Pfizer Inc. Extended Oral Antibiotics Product Portfolios and Specifications
Table 94. Pfizer Inc. Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
Table 95. Pfizer Inc. Main Business

Table 96. Pfizer Inc. Latest Developments
Table 97. GSK plc. Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors
Table 98. GSK plc. Extended Oral Antibiotics Product Portfolios and Specifications
Table 99. GSK plc. Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
Table 100. GSK plc. Main Business
Table 101. GSK plc. Latest Developments
Table 102. Merck & Co., Inc. Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors
Table 103. Merck & Co., Inc. Extended Oral Antibiotics Product Portfolios and Specifications
Table 104. Merck & Co., Inc. Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
Table 105. Merck & Co., Inc. Main Business
Table 106. Merck & Co., Inc. Latest Developments
Table 107. Novartis AG Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors
Table 108. Novartis AG Extended Oral Antibiotics Product Portfolios and Specifications
Table 109. Novartis AG Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
Table 110. Novartis AG Main Business
Table 111. Novartis AG Latest Developments
Table 112. Sanofi S.A. Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors
Table 113. Sanofi S.A. Extended Oral Antibiotics Product Portfolios and Specifications
Table 114. Sanofi S.A. Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
Table 115. Sanofi S.A. Main Business
Table 116. Sanofi S.A. Latest Developments
Table 117. Teva Pharmaceutical Industries Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors
Table 118. Teva Pharmaceutical Industries Extended Oral Antibiotics Product Portfolios and Specifications
Table 119. Teva Pharmaceutical Industries Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
Table 120. Teva Pharmaceutical Industries Main Business
Table 121. Teva Pharmaceutical Industries Latest Developments
Table 122. Viartis Inc. Basic Information, Extended Oral Antibiotics Manufacturing Base,

Sales Area and Its Competitors

Table 123. Viatris Inc. Extended Oral Antibiotics Product Portfolios and Specifications

Table 124. Viatris Inc. Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 125. Viatris Inc. Main Business

Table 126. Viatris Inc. Latest Developments

Table 127. Aurobindo Pharma Ltd Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors

Table 128. Aurobindo Pharma Ltd Extended Oral Antibiotics Product Portfolios and Specifications

Table 129. Aurobindo Pharma Ltd Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 130. Aurobindo Pharma Ltd Main Business

Table 131. Aurobindo Pharma Ltd Latest Developments

Table 132. Sun Pharmaceutical Industries Ltd Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors

Table 133. Sun Pharmaceutical Industries Ltd Extended Oral Antibiotics Product Portfolios and Specifications

Table 134. Sun Pharmaceutical Industries Ltd Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 135. Sun Pharmaceutical Industries Ltd Main Business

Table 136. Sun Pharmaceutical Industries Ltd Latest Developments

Table 137. Dr. Reddy's Laboratories Ltd Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors

Table 138. Dr. Reddy's Laboratories Ltd Extended Oral Antibiotics Product Portfolios and Specifications

Table 139. Dr. Reddy's Laboratories Ltd Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 140. Dr. Reddy's Laboratories Ltd Main Business

Table 141. Dr. Reddy's Laboratories Ltd Latest Developments

Table 142. Cipla Ltd Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors

Table 143. Cipla Ltd Extended Oral Antibiotics Product Portfolios and Specifications

Table 144. Cipla Ltd Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 145. Cipla Ltd Main Business

Table 146. Cipla Ltd Latest Developments

Table 147. Lupin Ltd Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors

Table 148. Lupin Ltd Extended Oral Antibiotics Product Portfolios and Specifications

Table 149. Lupin Ltd Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 150. Lupin Ltd Main Business

Table 151. Lupin Ltd Latest Developments

Table 152. Zhejiang Hisun Pharmaceutical Co., Ltd Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors

Table 153. Zhejiang Hisun Pharmaceutical Co., Ltd Extended Oral Antibiotics Product Portfolios and Specifications

Table 154. Zhejiang Hisun Pharmaceutical Co., Ltd Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 155. Zhejiang Hisun Pharmaceutical Co., Ltd Main Business

Table 156. Zhejiang Hisun Pharmaceutical Co., Ltd Latest Developments

Table 157. Takeda Pharmaceutical Company Ltd Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors

Table 158. Takeda Pharmaceutical Company Ltd Extended Oral Antibiotics Product Portfolios and Specifications

Table 159. Takeda Pharmaceutical Company Ltd Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 160. Takeda Pharmaceutical Company Ltd Main Business

Table 161. Takeda Pharmaceutical Company Ltd Latest Developments

Table 162. Daiichi Sankyo Company Ltd Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors

Table 163. Daiichi Sankyo Company Ltd Extended Oral Antibiotics Product Portfolios and Specifications

Table 164. Daiichi Sankyo Company Ltd Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 165. Daiichi Sankyo Company Ltd Main Business

Table 166. Daiichi Sankyo Company Ltd Latest Developments

Table 167. Meiji Seika Pharma Co., Ltd Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors

Table 168. Meiji Seika Pharma Co., Ltd Extended Oral Antibiotics Product Portfolios and Specifications

Table 169. Meiji Seika Pharma Co., Ltd Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 170. Meiji Seika Pharma Co., Ltd Main Business

Table 171. Meiji Seika Pharma Co., Ltd Latest Developments

Table 172. Boryung Co., Ltd Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors

Table 173. Boryung Co., Ltd Extended Oral Antibiotics Product Portfolios and Specifications

Table 174. Boryung Co., Ltd Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 175. Boryung Co., Ltd Main Business

Table 176. Boryung Co., Ltd Latest Developments

Table 177. Orchid Pharma Ltd Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors

Table 178. Orchid Pharma Ltd Extended Oral Antibiotics Product Portfolios and Specifications

Table 179. Orchid Pharma Ltd Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 180. Orchid Pharma Ltd Main Business

Table 181. Orchid Pharma Ltd Latest Developments

Table 182. CSPC Pharmaceutical Group Ltd Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors

Table 183. CSPC Pharmaceutical Group Ltd Extended Oral Antibiotics Product Portfolios and Specifications

Table 184. CSPC Pharmaceutical Group Ltd Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 185. CSPC Pharmaceutical Group Ltd Main Business

Table 186. CSPC Pharmaceutical Group Ltd Latest Developments

Table 187. Aspen Pharmacare Holdings Ltd Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors

Table 188. Aspen Pharmacare Holdings Ltd Extended Oral Antibiotics Product Portfolios and Specifications

Table 189. Aspen Pharmacare Holdings Ltd Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 190. Aspen Pharmacare Holdings Ltd Main Business

Table 191. Aspen Pharmacare Holdings Ltd Latest Developments

Table 192. North China Pharmaceutical Group Corp Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors

Table 193. North China Pharmaceutical Group Corp Extended Oral Antibiotics Product Portfolios and Specifications

Table 194. North China Pharmaceutical Group Corp Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 195. North China Pharmaceutical Group Corp Main Business

Table 196. North China Pharmaceutical Group Corp Latest Developments

Table 197. Shandong Lukang Pharmaceutical Co., Ltd Basic Information, Extended

Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors

Table 198. Shandong Lukang Pharmaceutical Co., Ltd Extended Oral Antibiotics Product Portfolios and Specifications

Table 199. Shandong Lukang Pharmaceutical Co., Ltd Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 200. Shandong Lukang Pharmaceutical Co., Ltd Main Business

Table 201. Shandong Lukang Pharmaceutical Co., Ltd Latest Developments

Table 202. Zentiva Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors

Table 203. Zentiva Extended Oral Antibiotics Product Portfolios and Specifications

Table 204. Zentiva Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 205. Zentiva Main Business

Table 206. Zentiva Latest Developments

Table 207. RedHill Biopharma Ltd Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors

Table 208. RedHill Biopharma Ltd Extended Oral Antibiotics Product Portfolios and Specifications

Table 209. RedHill Biopharma Ltd Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 210. RedHill Biopharma Ltd Main Business

Table 211. RedHill Biopharma Ltd Latest Developments

Table 212. TaiGen Biotechnology Co., Ltd Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors

Table 213. TaiGen Biotechnology Co., Ltd Extended Oral Antibiotics Product Portfolios and Specifications

Table 214. TaiGen Biotechnology Co., Ltd Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 215. TaiGen Biotechnology Co., Ltd Main Business

Table 216. TaiGen Biotechnology Co., Ltd Latest Developments

Table 217. Taiwan Biotech Co., Ltd Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors

Table 218. Taiwan Biotech Co., Ltd Extended Oral Antibiotics Product Portfolios and Specifications

Table 219. Taiwan Biotech Co., Ltd Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 220. Taiwan Biotech Co., Ltd Main Business

Table 221. Taiwan Biotech Co., Ltd Latest Developments

Table 222. Centrient Pharmaceuticals Basic Information, Extended Oral Antibiotics

Manufacturing Base, Sales Area and Its Competitors

Table 223. Centrient Pharmaceuticals Extended Oral Antibiotics Product Portfolios and Specifications

Table 224. Centrient Pharmaceuticals Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 225. Centrient Pharmaceuticals Main Business

Table 226. Centrient Pharmaceuticals Latest Developments

Table 227. Nabriva Therapeutics plc Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors

Table 228. Nabriva Therapeutics plc Extended Oral Antibiotics Product Portfolios and Specifications

Table 229. Nabriva Therapeutics plc Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 230. Nabriva Therapeutics plc Main Business

Table 231. Nabriva Therapeutics plc Latest Developments

Table 232. Melinta Therapeutics Inc. Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors

Table 233. Melinta Therapeutics Inc. Extended Oral Antibiotics Product Portfolios and Specifications

Table 234. Melinta Therapeutics Inc. Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 235. Melinta Therapeutics Inc. Main Business

Table 236. Melinta Therapeutics Inc. Latest Developments

Table 237. Lonza Group Basic Information, Extended Oral Antibiotics Manufacturing Base, Sales Area and Its Competitors

Table 238. Lonza Group Extended Oral Antibiotics Product Portfolios and Specifications

Table 239. Lonza Group Extended Oral Antibiotics Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)

Table 240. Lonza Group Main Business

Table 241. Lonza Group Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Extended Oral Antibiotics
- Figure 2. Extended Oral Antibiotics Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Extended Oral Antibiotics Sales Growth Rate 2021-2032 (K Units)
- Figure 7. Global Extended Oral Antibiotics Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Extended Oral Antibiotics Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Extended Oral Antibiotics Sales Market Share by Country/Region (2025)
- Figure 10. Extended Oral Antibiotics Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Extended Release Oral Antibiotics
- Figure 12. Product Picture of Oral Penicillin Derivatives
- Figure 13. Product Picture of Oral Cephalosporins
- Figure 14. Product Picture of Oral Macrolides
- Figure 15. Product Picture of Others
- Figure 16. Global Extended Oral Antibiotics Sales Market Share by Type in 2026
- Figure 17. Global Extended Oral Antibiotics Revenue Market Share by Type (2021-2026)
- Figure 18. Product Picture of Narrow Spectrum Antibiotics
- Figure 19. Product Picture of Broad Spectrum Antibiotics
- Figure 20. Global Extended Oral Antibiotics Sales Market Share by Antibiotic Spectrum in 2026
- Figure 21. Global Extended Oral Antibiotics Revenue Market Share by Antibiotic Spectrum (2021-2026)
- Figure 22. Product Picture of Short Extended Course (7-10 Days)
- Figure 23. Product Picture of Standard Extended Course (10-14 Days)
- Figure 24. Product Picture of Prolonged Course (14-28 Days)
- Figure 25. Product Picture of Long Term Suppression (>28 Days to Months)
- Figure 26. Product Picture of Others
- Figure 27. Global Extended Oral Antibiotics Sales Market Share by Treatment Duration in 2026
- Figure 28. Global Extended Oral Antibiotics Revenue Market Share by Treatment Duration (2021-2026)

- Figure 29. Extended Oral Antibiotics Consumed in Hospitals
- Figure 30. Global Extended Oral Antibiotics Market: Hospitals (2021-2026) & (K Units)
- Figure 31. Extended Oral Antibiotics Consumed in Clinics
- Figure 32. Global Extended Oral Antibiotics Market: Clinics (2021-2026) & (K Units)
- Figure 33. Extended Oral Antibiotics Consumed in Pharmacy
- Figure 34. Global Extended Oral Antibiotics Market: Pharmacy (2021-2026) & (K Units)
- Figure 35. Extended Oral Antibiotics Consumed in Others
- Figure 36. Global Extended Oral Antibiotics Market: Others (2021-2026) & (K Units)
- Figure 37. Global Extended Oral Antibiotics Sale Market Share by Application (2025)
- Figure 38. Global Extended Oral Antibiotics Revenue Market Share by Application in 2025
- Figure 39. Extended Oral Antibiotics Sales by Company in 2025 (K Units)
- Figure 40. Global Extended Oral Antibiotics Sales Market Share by Company in 2025
- Figure 41. Extended Oral Antibiotics Revenue by Company in 2025 (\$ millions)
- Figure 42. Global Extended Oral Antibiotics Revenue Market Share by Company in 2025
- Figure 43. Global Extended Oral Antibiotics Sales Market Share by Geographic Region (2021-2026)
- Figure 44. Global Extended Oral Antibiotics Revenue Market Share by Geographic Region in 2025
- Figure 45. Americas Extended Oral Antibiotics Sales 2021-2026 (K Units)
- Figure 46. Americas Extended Oral Antibiotics Revenue 2021-2026 (\$ millions)
- Figure 47. APAC Extended Oral Antibiotics Sales 2021-2026 (K Units)
- Figure 48. APAC Extended Oral Antibiotics Revenue 2021-2026 (\$ millions)
- Figure 49. Europe Extended Oral Antibiotics Sales 2021-2026 (K Units)
- Figure 50. Europe Extended Oral Antibiotics Revenue 2021-2026 (\$ millions)
- Figure 51. Middle East & Africa Extended Oral Antibiotics Sales 2021-2026 (K Units)
- Figure 52. Middle East & Africa Extended Oral Antibiotics Revenue 2021-2026 (\$ millions)
- Figure 53. Americas Extended Oral Antibiotics Sales Market Share by Country in 2025
- Figure 54. Americas Extended Oral Antibiotics Revenue Market Share by Country (2021-2026)
- Figure 55. Americas Extended Oral Antibiotics Sales Market Share by Type (2021-2026)
- Figure 56. Americas Extended Oral Antibiotics Sales Market Share by Application (2021-2026)
- Figure 57. United States Extended Oral Antibiotics Revenue Growth 2021-2026 (\$ millions)
- Figure 58. Canada Extended Oral Antibiotics Revenue Growth 2021-2026 (\$ millions)

Figure 59. Mexico Extended Oral Antibiotics Revenue Growth 2021-2026 (\$ millions)

Figure 60. Brazil Extended Oral Antibiotics Revenue Growth 2021-2026 (\$ millions)

Figure 61. APAC Extended Oral Antibiotics Sales Market Share by Region in 2025

Figure 62. APAC Extended Oral Antibiotics Revenue Market Share by Region (2021-2026)

Figure 63. APAC Extended Oral Antibiotics Sales Market Share by Type (2021-2026)

Figure 64. APAC Extended Oral Antibiotics Sales Market Share by Application (2021-2026)

Figure 65. China Extended Oral Antibiotics Revenue Growth 2021-2026 (\$ millions)

Figure 66. Japan Extended Oral Antibiotics Revenue Growth 2021-2026 (\$ millions)

Figure 67. South Korea Extended Oral Antibiotics Revenue Growth 2021-2026 (\$ millions)

Figure 68. Southeast Asia Extended Oral Antibiotics Revenue Growth 2021-2026 (\$ millions)

Figure 69. India Extended Oral Antibiotics Revenue Growth 2021-2026 (\$ millions)

Figure 70. Australia Extended Oral Antibiotics Revenue Growth 2021-2026 (\$ millions)

Figure 71. China Taiwan Extended Oral Antibiotics Revenue Growth 2021-2026 (\$ millions)

Figure 72. Europe Extended Oral Antibiotics Sales Market Share by Country in 2025

Figure 73. Europe Extended Oral Antibiotics Revenue Market Share by Country (2021-2026)

Figure 74. Europe Extended Oral Antibiotics Sales Market Share by Type (2021-2026)

Figure 75. Europe Extended Oral Antibiotics Sales Market Share by Application (2021-2026)

Figure 76. Germany Extended Oral Antibiotics Revenue Growth 2021-2026 (\$ millions)

Figure 77. France Extended Oral Antibiotics Revenue Growth 2021-2026 (\$ millions)

Figure 78. UK Extended Oral Antibiotics Revenue Growth 2021-2026 (\$ millions)

Figure 79. Italy Extended Oral Antibiotics Revenue Growth 2021-2026 (\$ millions)

Figure 80. Russia Extended Oral Antibiotics Revenue Growth 2021-2026 (\$ millions)

Figure 81. Middle East & Africa Extended Oral Antibiotics Sales Market Share by Country (2021-2026)

Figure 82. Middle East & Africa Extended Oral Antibiotics Sales Market Share by Type (2021-2026)

Figure 83. Middle East & Africa Extended Oral Antibiotics Sales Market Share by Application (2021-2026)

Figure 84. Egypt Extended Oral Antibiotics Revenue Growth 2021-2026 (\$ millions)

Figure 85. South Africa Extended Oral Antibiotics Revenue Growth 2021-2026 (\$ millions)

Figure 86. Israel Extended Oral Antibiotics Revenue Growth 2021-2026 (\$ millions)

Figure 87. Turkey Extended Oral Antibiotics Revenue Growth 2021-2026 (\$ millions)

Figure 88. GCC Countries Extended Oral Antibiotics Revenue Growth 2021-2026 (\$ millions)

Figure 89. Manufacturing Cost Structure Analysis of Extended Oral Antibiotics in 2026

Figure 90. Manufacturing Process Analysis of Extended Oral Antibiotics

Figure 91. Industry Chain Structure of Extended Oral Antibiotics

Figure 92. Channels of Distribution

Figure 93. Global Extended Oral Antibiotics Sales Market Forecast by Region (2027-2032)

Figure 94. Global Extended Oral Antibiotics Revenue Market Share Forecast by Region (2027-2032)

Figure 95. Global Extended Oral Antibiotics Sales Market Share Forecast by Type (2027-2032)

Figure 96. Global Extended Oral Antibiotics Revenue Market Share Forecast by Type (2027-2032)

Figure 97. Global Extended Oral Antibiotics Sales Market Share Forecast by Application (2027-2032)

Figure 98. Global Extended Oral Antibiotics Revenue Market Share Forecast by Application (2027-2032)

I would like to order

Product name: Global Extended Oral Antibiotics Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G9332D1F97CEEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G9332D1F97CEEN.html>